Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 45
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
1/29/2008
 
First Published:
12/8/2006
1.
Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV, Phase III
Treatment
Active
21 and under
Other
GPOH-NB2004
EU-20661, NCT00410631
2.
Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Supportive care, Treatment
Active
18 and over
Other
2006-00055-18
NCT00415103
3.
Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Supportive care, Treatment
Active
18 to 75
Other
UMCN-AKF 07.02
EudraCTnr 2007-003347-73, NCT00588835
Last Modified:
4/28/2008
 
First Published:
5/21/2007
4.
Phase II/III Randomized Study of Therapy Optimization Comprising Induction, Consolidation, and Intensification Regimens Followed By CNS Radiotherapy and Maintenance Therapy Comprising Thioguanine and Cytarabine in Pediatric Patients With Standard-Risk or High-Risk Acute Myeloid Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and under
Other
UCHM-AML-BFM-2004
UCHM-BfArM 4022064, NCT00111345, UCHM-DKH 50-2728, EU-20723, AML-BFM 2004
5.
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
25 to 65
Other
JALSG ALL202-O
NCT00131027
Last Modified:
1/13/2009
 
First Published:
9/23/2006
6.
Phase III Randomized Study of Low-Dose Versus High-Dose Vincristine and Combination Chemotherapy in Pediatric Patients With Intermediate-Risk Relapsed B-Precursor Acute Lymphoblastic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
1 to under 30
NCI
COG-AALL0433
AALL0433, NCT00381680
Last Modified:
6/19/2008
 
First Published:
2/5/2007
7.
Phase III Randomized Study of Combination Chemotherapy in Pediatric Patients With Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Diagnostic, Treatment
Active
Under 18
Other
EURONET-PHL-C1
EU-20703, EUDRACT-2006-000995-33, NCT00433459, CCLG-HD-2007-10
Last Modified:
12/31/2008
 
First Published:
4/2/2008
8.
Phase III Study of Induction Therapy Comprising Vincristine, High-Dose Methotrexate, Leucovorin Calcium, Etoposide, Cisplatin, and Cyclophosphamide Followed by 3-Dimensional Conformal Radiotherapy and High-Dose Consolidation Therapy Comprising Carboplatin, Thiotepa, and Autologous Peripheral Blood Stem Cell Rescue in Pediatric Patients With Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Treatment
Active
21 and under at the time of definitive surgery
NCI
COG-ACNS0333
ACNS0333, NCT00653068
9.
Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-Cisplatin for Extensive Disease Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
D0750018
D0750018, NCT00660504
10.
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
30 and under
NCI, Other
OS2008
NCT00667342
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute